Attovia Therapeutics, Inc. (ATTO) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $4.97M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-79.00K; Retained Earnings (Accumulated Deficit)USD $-150.35M.
- 2026-03-31: Common Stock, Value, IssuedUSD (m); Additional Paid in CapitalUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD (m).
- 2025-12-31: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $3.47M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $99.00K; Retained Earnings (Accumulated Deficit)USD $-111.01M.
- 2025-06-30: Common Stock, Value, IssuedUSD (m); Additional Paid in CapitalUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD (m).
Attovia Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD |
|---|---|---|---|---|---|
| 2026-06-30 | $1.00K | $4.97M | $-79.00K | $-150.35M | $-145.46M |
| 2026-03-31 | (m) | (m) | (m) | (m) | $-125.52M |
| 2025-12-31 | $1.00K | $3.47M | $99.00K | $-111.01M | $-107.44M |
| 2025-06-30 | (m) | (m) | (m) | (m) | $-75.53M |
| 2025-03-31 | (m) | (m) | (m) | (m) | $-61.76M |
| 2024-12-31 | (m) | (m) | (m) | (m) | $-46.83M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |